BioMarCare

Company Overview

Snapshot

Founded in January 2002, BioMarCare had 1–10 employees. The company raised $1.9M across three funding rounds from two investors. In March 2012, BioMarCare secured a Seed round from Micromedic.

Business overview

BioMarCare specializes in developing tumor biomarker technologies for the early diagnosis of cancer. The company utilizes a multi-biomarker panel approach to create molecular blood tests and tissue-based diagnostic (IHC) tests, aiming for high specificity and sensitivity in cancer detection. Its product, Colon-MarCarePlex, is designed as an accurate, patient-friendly colorectal cancer screening test that measures gene expression biomarkers. Additionally, BioMarCare's mCRC-STRAT is a semi-quantitative IHC assay that predicts patient responses to drugs targeting the epidermal growth factor receptor. The company operates within the Health Tech & Life Sciences sector, focusing on Digital Medical Diagnostics and serving the healthcare industry, particularly laboratories.

Company Intelligence Q&A

What is BioMarCare's primary focus?

BioMarCare focuses on developing tumor biomarker technologies for the early diagnosis of cancer, utilizing multi-biomarker panel approaches for molecular blood tests and tissue-based diagnostic tests.

What is the Colon-MarCarePlex product?

Colon-MarCarePlex is BioMarCare's colorectal cancer screening test that measures the expression of several genes as biomarkers to detect colorectal cancer and advanced adenoma polyps.

What is the purpose of MCRC-Strat?

MCRC-Strat is BioMarCare's semi-quantitative IHC assay that uses a protein biomarker combination to predict patient responses to drugs targeting the epidermal growth factor receptor.

When was BioMarCare founded?

BioMarCare was founded in January 2002.

What was the company's status as of August 2020?

As of August 2020, BioMarCare ceased to operate.